· Singmed independently developed this multi-dose blister DPI platform. The platform has been used in drug-device combination development programs that completed NMPA bioequivalence evaluation in 2022. Additional development programs are ongoing with pharmaceutical partners. The platform supports customization of aerosol performance, inspiratory resistance, dose-counting functions and industrialization requirements.

· Counting window for accurate indication of dosage

· Easy/Effortless compliance management. Suitable/ Appropriate for the elderly, Childrens and individuals with limited respiratory capacity.

· Inspiratory resistance range 0.03 to 0.06（kPa·s/L）